Accepted at 12:52 a.m. Nov, 01, 2023 by dollajas
Author: Tahseen
Related Note: 1495818787111
Rationale for change

type is way too vague could be type of receptor inhibition etc I think this is better though prefer competitive, non competitive what do you guys think

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#OME_banner #AK_Step1_v12::#AMBOSS::V-0Gwi #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::03_Kinase_Inhibitors_&_Monoclonal_Antibodies::01_Kinase_Inhibitors::zanki_extra #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::09_Leukemias_and_Lymphomas::02_Chronic_Myeloid_Leukemia #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::18_Imatinib/Dasatinib #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::01_Acute_Leukemias_SOAP #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::19_Anticancer_small_molecule_inhibitors::*Imatinib_Dasatinib_Nilotinib #PANCE::HEME::neoplasms_premalignancies_malignancies #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::11_Cell_Cycle_Independent_Drug_Targets #AK_Step1_v12::#Pixorize::02_Immunology::07_Leukemias_&_Lymphomas::04_Chronic_Myelogenous_Leukemia_(CML) #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::02_Chronic_Leukemias_SOAP #AK_Step1_v12::^Other::^EXPN